Perflow Medical

Company Overview

Snapshot

Founded in March 2010 by Danny Farin, Eyal Orion, Avi Rappaport, and Gilad Cibulski, Perflow Medical operates with 11–50 employees. The company has raised $13.6 million across 2 funding rounds from 5 investors. In January 2022, Perflow Medical was acquired by an unnamed Chinese private equity firm for approximately $100 million.

Business overview

Perflow Medical is a Health Tech & Life Sciences company focused on developing, manufacturing, and commercializing neurovascular interventional products. The company's core technology, the CEREBRAL NET platform, is used to create devices for thrombectomy, aneurysm neck bridging, and flow diversion. Perflow Medical's products, including the Stream Dynamic Neuro-Thrombectomy Net and the Cascade Non-Occlusive Remodeling Net, are CE marked and available in Europe, serving the healthcare provider market.

Strategic signal

In January 2022, Perflow Medical was acquired by an unnamed Chinese private equity firm for approximately $100 million. This acquisition signals strong validation of Perflow Medical's neurovascular technology and its potential in the global medical device market, indicating a successful exit for early investors and a strategic growth trajectory under new ownership.

Company Intelligence Q&A

What was a significant financial event for Perflow Medical?

In January 2022, Perflow Medical was acquired by an unnamed Chinese private equity firm for approximately $100 million. This marked a significant exit for the company, which develops neurovascular treatments for hemorrhagic and ischemic strokes.

When did Perflow Medical expand its product portfolio with the Stream™17 Dynamic Neuro-Thrombectomy Net?

In April 2021, Perflow Medical announced the successful clinical use of the Stream™17 Dynamic Neuro-Thrombectomy Net. This device, based on the company's CEREBRAL NET technology, expands the range of brain vessels that can be treated.

What was the first clinical use of the Cascade™ 17 Dynamic Non-Occlusive Remodeling Net?

In March 2021, Perflow Medical announced the first clinical use of the Cascade™ 17 Dynamic Non-Occlusive Remodeling Net in the European market. This neurovascular device optimizes non-occlusive support during coil embolization of intracranial aneurysms.

When did Perflow Medical receive CE Mark approval for the Cascade Agile?

In October 2019, Perflow Medical received CE Mark approval for the Cascade Agile Non-Occlusive Remodeling Net. This expanded their product family for neurovascular treatment, providing better control for distal and tortuous vessel anatomy during coil embolization of intracranial aneurysms.

When did Perflow Medical expand its intellectual property coverage for its neuro-interventional devices?

In January 2019, Perflow Medical announced the issuance of four international patents, expanding its global IP coverage for its neuro-interventional devices. This brought their portfolio to eight issued patents, including new patents from the European Patent Office, China National Intellectual Property Administration, and Japanese Patent Office.